Deferasirox in MDS Patients With Transfusion-Caused Iron Overload—a Phase-Ii Study

Annals of Hematology - Germany
doi 10.1007/s00277-008-0588-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

PO-0161 Treatment of Iron Overload With Deferasirox in the Patients With Thalassaemia Major

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2014English

Patient-Reported Outcomes From a Randomized Phase II Study of the Deferasirox Film-Coated Tablet in Patients With Transfusion-Dependent Anemias

Health and Quality of Life Outcomes
MedicineEnvironmentalPublic HealthOccupational Health
2018English

Deferasirox Reduces Oxidative Stress in Patients With Transfusion Dependency

Journal of Clinical Medicine Research
2013English

Iron Overload in Non-Transfusion-Dependent Thalassemia

Thalassemia Reports
2013English

Maitake Mushroom Extract in Myelodysplastic Syndromes (MDS): A Phase II Study

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2014English

Real-World Evidence of Iron Chelation Therapy in Transfusion-Dependent MDS Patients: A Portuguese Hospital Registry

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Hematologic Responses to Deferasirox Therapy in Transfusion-Dependent Patients With Myelodysplastic Syndromes

Haematologica
Hematology
2012English

Daily Alternating Deferasirox and Deferiprone Therapy Successfully Controls Iron Accumulation in Untreatable Transfusion Dependent Thalassemia Patients

American Journal of Hematology
Hematology
2018English

Transplant Conditioning With Treosulfan/Fludarabine With or Without TBI. A Randomized Phase II Trial in Patients With MDS and AML

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy